Sunesis Pharmaceuticals (SNSS) Tops Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
Sunesis Pharmaceuticals Inc. (SNSS) PT Lowered to $6 at Oppenheimer, Stays Bullish
March 8, 2019 1:13 PM ESTOppenheimer analyst Hartaj Singh lowered the price target on Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) to $6.00 (from $7.00) while maintaining a Outperform rating.
With the company enrolling up to 6 evaluable patients at the first therapeutic dose level of 100mg BID, we anticipate the June... More